{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:46:21Z","timestamp":1759513581447},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.suronc.2009.02.015","type":"journal-article","created":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T08:40:29Z","timestamp":1238748029000},"page":"38-45","source":"Crossref","is-referenced-by-count":17,"title":["A meta-analysis of chemotherapy regimen Fluorouracil\/Leucovorin\/Oxaliplatin Compared with Fluorouracil\/Leucovorin in treating advanced colorectal cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Mian Ling","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Hua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu Sen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Hua","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.suronc.2009.02.015_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal caner","volume":"22","author":"Goldberg","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.suronc.2009.02.015_bib2","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.23091","article-title":"FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study","volume":"110","author":"Figer","year":"2007","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.suronc.2009.02.015_bib3","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.suronc.2009.02.015_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.suronc.2007.08.008","article-title":"Palliation of colorectal cancer","volume":"16","author":"Wasserberg","year":"2007","journal-title":"Surgical Oncology"},{"key":"10.1016\/j.suronc.2009.02.015_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0753-3322(89)90004-8","article-title":"Antitumor activity of a new platinum complex, oxalato(trans-1-1, 2-diaminocyclohexane) platinum (II): new experimental data","volume":"43","author":"Tashiro","year":"1989","journal-title":"Biomedicine & Phamacotherapy"},{"key":"10.1016\/j.suronc.2009.02.015_bib6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/00001813-199710000-00009","article-title":"Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers","volume":"8","author":"Raymond","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.suronc.2009.02.015_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.9-1-8","article-title":"FDA drup approval summaries: oxaliplatin","volume":"9","author":"Ibrahim","year":"2004","journal-title":"The Oncologist"},{"key":"10.1016\/j.suronc.2009.02.015_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/annonc\/mdj104","article-title":"Randomised phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU\/folinic acid in first-line treatment of advanced colorectal cancer","volume":"17","author":"Hospers","year":"2006","journal-title":"Annals of Oncology"},{"issue":"23","key":"10.1016\/j.suronc.2009.02.015_bib9","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1200\/JCO.2004.03.119","article-title":"Randomized multicenter phase II trial of bolus plus infusional fluorouracil\/leucovorin compared with fluorouracil\/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer","volume":"22","author":"Kemeny","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.suronc.2009.02.015_bib10","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"Rothernberg","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.suronc.2009.02.015_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phases III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"Journal of Clinical Oncology"}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740409000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740409000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T09:08:21Z","timestamp":1558256901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740409000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0960740409000371"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2009.02.015","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}